A5022019360- Lung Cancer Treatments and Mutations
- Protein Tyrosine Phosphatases
- Cancer Immunotherapy and Biomarkers
- RNA modifications and cancer
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer Research and Treatments
- Gastric Cancer Management and Outcomes
- Cancer Mechanisms and Therapy
- Cancer, Hypoxia, and Metabolism
- Ferroptosis and cancer prognosis
- Immunotherapy and Immune Responses
- Lung Cancer Diagnosis and Treatment
- Cancer Cells and Metastasis
- Synthesis and biological activity
- PI3K/AKT/mTOR signaling in cancer
- Galectins and Cancer Biology
- Viral-associated cancers and disorders
- Cancer therapeutics and mechanisms
- Fatty Acid Research and Health
- Respiratory and Cough-Related Research
- Advanced Drug Delivery Systems
- Metastasis and carcinoma case studies
- Optical Imaging and Spectroscopy Techniques
- Salivary Gland Tumors Diagnosis and Treatment
Okayama Red Cross General Hospital
2024
Okayama University
2021-2023
Okayama University Hospital
2019-2022
Meijo University
2018
Meiji Pharmaceutical University
2018
National Hospital Organization
2017
Okayama Medical Center
2017
Tsuyama Chuo Hospital
2017
Tokyo Medical University
2013
Abstract The relationships between the therapeutic effects of immune checkpoint inhibitors (ICIs) and intestinal flora have attracted increasing attention. However, oral probiotics on efficacies ICIs used to treat non‐small‐cell lung cancer (NSCLC) remain unclear. We investigated in patients treated with without chemotherapy. advanced NSCLC ICI monotherapy or combination chemotherapy using Okayama Lung Cancer Study Group Immunotherapy Database (OLCSG‐ID) Immunochemotherapy (OLCSG‐ICD). In...
Abstract Molecular agents targeting the epidermal growth factor receptor ( EGFR )‐, anaplastic lymphoma kinase ALK )‐ or c‐ ros oncogene 1 ROS1 ) alterations have revolutionized treatment of oncogene‐driven non‐small‐cell lung cancer (NSCLC). However, emergence acquired resistance remains a significant challenge, limiting wider clinical success these molecular targeted therapies. In this study, we investigated efficacy various agents, including erlotinib, alectinib, and crizotinib, combined...
Abstract Epidermal growth factor receptor (EGFR) is the most frequently mutated driver oncogene in nonsmoking-related, non–small cell lung cancer (NSCLC). EGFR-mutant NSCLC has a noninflamed tumor microenvironment (TME), with low infiltration by CD8+ T cells and, thus, immune-checkpoint inhibitors, such as antiprogrammed death-1 (anti–PD-1), have weak antitumor effects. Here, we showed that T-cell responses were induced an EGFR-tyrosine kinase inhibitor (TKI) syngeneic Egfr-mutant tumors,...
Mucosa-associated lymphoid tissue lymphoma is a common type of primary pulmonary carcinoma, but the presence polypoid nodules extremely rare. We herein report two cases with multiple in trachea. One case involved and airway stenosis mimicking asthma; other had concurrent nontuberculous mycobacterial infection. The diagnosis both was confirmed by bronchoscopy. were sensitive to radiotherapy chemotherapy, respectively.
Exon 18 delE709_T710insD is an extremely rare mutation in epidermal growth factor receptor (EGFR) non-small-cell lung cancer (NSCLC); the efficacy of EGFR tyrosine kinase inhibitors against this remains unclear. In case report, we report a NSCLC harboring exon that was not detected by commercially available assay, but next-generation sequencing panel. A 56-year old female patient with advanced diagnosed as EGFR-mutation-negative using PNAClamp method. ALK rearrangement also absent and she...
Abstract After molecular-targeted therapy, some cancer cells may remain that are resistant to therapies targeting oncogene alterations, such as those in the genes encoding EGFR and anaplastic lymphoma kinase (ALK) well c-ros 1 (ROS1). The mechanisms underlying this type of resistance unknown. In article, we report potential role Src homology 2 domain–containing phosphatase (SHP2) residual ALK/ROS1/EGFR-altered non–small cell lung (NSCLC). Molecular-targeted failed inhibit ERK signaling...
Gilteritinib is a multitarget tyrosine kinase inhibitor (TKI), approved for the treatment of FLT3-mutant acute myeloid leukemia, with broad range activity against several kinases including anaplastic lymphoma (ALK). This study investigated efficacy gilteritinib ALK-rearranged non-small cell lung cancers (NSCLC). To this end, we assessed effects on proliferation, apoptosis, and acquired resistance responses in NSCLC lines mouse xenograft tumor models compared its to alectinib, standard ALK...
Objectives: Combined immune checkpoint inhibitor (ICI) therapy and chemotherapy has become the standard treatment for advanced non-small-cell lung cancer (NSCLC). Pleural effusion (PE) is associated with poor outcomes among patients NSCLC undergoing chemotherapy. However, minimal data exists on PE combined ICI Therefore, we investigated how affects survival in this therapy. Methods: We identified from Okayama Lung Cancer Study Group−Immune Chemotherapy Database (OLCSG−ICD) between December...
Epidermal growth factor receptor (EGFR) mutations, such as exon 19 deletion and 21 L858R, are driver oncogenes of non-small cell lung cancer (NSCLC), with EGFR tyrosine kinase inhibitors (TKIs) being effective against EGFR-mutant NSCLC. However, the efficacy EGFR-TKIs is transient eventually leads to acquired resistance. Herein, we focused on significance cycle factors a mechanism attenuate effect in NSCLC before emergence resistance.Using several lines, investigated NSCLC.In certain cells...
Atypical tumor responses such as pseudo-progression or hyper-progression sometimes occur during immune check point inhibitor therapy. Distinct from both responses, we experienced a case of non-small cell lung cancer (NSCLC) with pseudo-relapse, in which development granulation mimicked relapse nivolumab A male advanced NSCLC started second-line After 15 cycles complete response, markers increasing and positron-emission computed tomography indicated hot spot the sigmoid colon. Laparoscopic...
Limited data are available on the frequency and significance of body weight loss during cancer therapy. This study investigated patients who experienced immune checkpoint inhibitor (ICI) plus chemotherapy for advanced non-small cell lung (NSCLC) impact treatment outcomes.
Bronchial thermoplasty is a novel procedure for patients with severe asthma showing stable lung function. We herein report two cases deteriorating The function tended to improve in one case, while the other case discontinued mepolizumab medication after procedure. Treatment was performed safely under general anesthesia both cases. use of bronchial may therefore be useful treatment
<p>Supplementary Figure 5. Combined use of RMC4550 with alectinib, crizotinib or osimertinib Immunoblots the indicated proteins in H3122 and ABC-19 cells treated alectinib (Alec, 100 nM), HCC78 ABC-20 (Cri, 1 µM) PC-9 HCC827 (Osi, nM). All cell lines were also RMC-4550 (RMC, 5 µM). Comb, combination. (B) Cell viability curves plotted for molecular-targeted drug alone (circles), (triangles) (5 (squares). drugs loaded 96 h. Error bars represent standard error.</p>
<div>Abstract<p>After molecular-targeted therapy, some cancer cells may remain that are resistant to therapies targeting oncogene alterations, such as those in the genes encoding <i>EGFR</i> and anaplastic lymphoma kinase (<i>ALK</i>) well c-ros 1 (<i>ROS1</i>). The mechanisms underlying this type of resistance unknown. In article, we report potential role Src homology 2 domain–containing phosphatase (SHP2) residual...
<p>Supplementary Figure 3. Combined use of SHP099 with alectinib, crizotinib or osimertinib Cell viability after treatment a single agent combination agents relative to the control (set 1). All drugs were loaded for 96 h. Error bars represent standard error. *P < 0.01 (one-way ANOVA and Bonferroni method). S, SHP099; A, alectinib; C, crizotinib; O, osimertinib.</p>
<p>Supplementary Figure 2. ROS1 TKI in combination with SHP099 (A) Immunoblots of the indicated proteins HCC78 and ABC-20 cells treated for 24 h DS-6051b (Ds, 100 nM) or without (SHP, 5 µM). Comb, combination. (B) RAS-GTP assay H3122 alectinib (Alec, nM), crizotinib (Cri, 1 µM) HCC827 osimertinib (Osi, h. All cell lines were also not (C) Cell viability curves (DS) alone (circles), (SHP) (triangles) DC6051b (5 (squares). drugs loaded 96 Error bars represent standard error.</p>
<p>Supplementary Figure 7. SHP2 compared to selumetinib in a xenograft mouse model. (A) Immunoblots of the PC-9 tumors treated with indicated agents for 7 days. (B) Body weight changes after combination therapy osimertinib and SHP099 or osimertnib mice. Error bars represent standard deviation. (C) alectinib H3122 (D) crizotinib ABC-20 Osi, osimertinib; Alec, alectinib; Cri, crizotinib; Selu, selumetinib; SHP, SHP099.</p>